Breaking News
Start for Free 0
🥇 First rule of investing? Know when to save! Up to 55% off Investing Pro before BLACK FRIDAY
CLAIM SALE
Close

Merck KGaA (MRCG)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
150.85 -0.50    -0.33%
08/11 - Closed. Currency in EUR
Type:  Equity
Market:  Germany
ISIN:  DE0006599905 
WKN:  659990
  • Volume: 245,844
  • Bid/Ask: 150.85 / 150.70
  • Day's Range: 150.35 - 152.95
Merck 150.85 -0.50 -0.33%

ETR:MRCG Financials

 
Gain a comprehensive overview of Merck financials. Assess key figures from the balance sheet and income statement. Explore essential metrics such as total assets, total liabilities, equity, revenue, and net income to understand the company’s overall financial performance.

Merck KGaA reported earnings results for the second quarter and six months ended June 30, 2024. For the second quarter, the company reported sales was EUR 5,352 million compared to EUR 5,302 million a year ago. Net income was EUR 607 million compared to EUR 704 million a year ago. Basic earnings per share from continuing operations was EUR 1.4 compared to EUR 1.62 a year ago. Diluted earnings per share from continuing operations was EUR 1.4 compared to EUR 1.62 a year ago.For the six months, sales was EUR 10,472 million compared to EUR 10,595 million a year ago. Net income was EUR 1,302 million compared to EUR 1,500 million a year ago. Basic earnings per share from continuing operations was EUR 2.99 compared to EUR 3.45 a year ago. Diluted earnings per share from continuing operations was EUR 2.99 compared to EUR 3.45 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

MRCG Income Statement

Gross margin TTM 58.42%
Operating margin TTM 16.36%
Net Profit margin TTM 12.58%
Return on Investment TTM 6.89%
 Total Revenue  Net Income
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Total Revenue 5352 5120 5225 5173
Gross Profit 3233 3009 2940 3011
Operating Income 793 931 708 984
Net Income 607 694 586 739

MRCG Balance Sheet

Quick Ratio MRQ 0.73
Current Ratio MRQ 1.31
LT Debt to Equity MRQ 25.15%
Total Debt to Equity MRQ 37.65%
 Total Assets  Total Liabilities
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Total Assets 49875 49504 48495 49906
Total Liabilities 21259 21430 21740 21611
Total Equity 28616 28074 26755 28295

MRCG Cash Flow Statement

Cash Flow/Share TTM 9.67
Revenue/Share TTM 48
Operating Cash Flow  8.67%
 Cash  Net Change in Cash
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 861 1035 1053 1255
Cash From Investing Activities -30 -689 -451 -350
Cash From Financing Activities -360 -107 -974 -302
Net Change in Cash 465 238 -383 604
* In Millions of EUR (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MRCG Comments

Write your thoughts about Merck KGAA O.N.
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Rajesh Mulchandani
Rajesh Mulchandani Oct 22, 2018 21:40
Saved. See Saved Items.
This comment has already been saved in your Saved Items
“The open door is never behind you; the open door is always before you. Quit looking at your past life and mistakes. Look unto Jesus who is the Author and Perfector of our faith. Your open door is not in the opportunity you missed ten years ago, it is not in some stuffs behind you that you can't get back. You can't gain your access by giving attention to your past life.
Rajesh Mulchandani
Rajesh Mulchandani Oct 22, 2018 21:39
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Enroll Now for Online Webinar to Learn Stock Market Techniques----------- Learn Technical Analysis and take the “RIGHT KNOWLEDGE” before you venture and make the stock market a profitable place…
Rajesh Mulchandani
Rajesh Mulchandani Oct 22, 2018 21:39
Saved. See Saved Items.
This comment has already been saved in your Saved Items
SELL SELL SELL ________MERK ____________ SELL SELL SELL SELL. . Click Here for more Information:- https://bit.ly/2PjBMiB
Ramesh Ji
Ramesh Ji Oct 13, 2018 16:12
Saved. See Saved Items.
This comment has already been saved in your Saved Items
“You need to have faith in yourself. Be brave and take risks. You don't have to have it all figured out to move forward.”
Ramesh Ji
Ramesh Ji Oct 13, 2018 16:10
Saved. See Saved Items.
This comment has already been saved in your Saved Items
BUY BUY BUY _______Merck KGaA (MERK). _____________ BUY  BUY  BUY  BUY
Mohit Chouhan
badboy_2 Apr 19, 2018 13:16
Saved. See Saved Items.
This comment has already been saved in your Saved Items
jet airways tgt done of 615. capvision.co.in
Mohit Chouhan
badboy_2 Apr 19, 2018 11:36
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Merck sell below 1740 TGT 1720/1700 SL1750..                             capvision.co.in. level of mohit chouhan
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email